News|Videos|July 30, 2026

Pharma Fundamentals: Hold Times in Biopharmaceuticals, an Introduction

This episode of Pharma Fundamentals provides an introduction to hold times in biopharmaceutical manufacturing and how they differ from hold times in small-molecule drug manufacturing.

In this Pharma Fundamentals episode, Robert Dream, managing director of HDR Company and a PharmTech Editorial Advisory Board member, explains hold times in biopharmaceutical manufacturing. A hold time is the maximum validated period an intermediate or product can sit between processing steps without harming quality, safety, purity, potency, or stability. Pauses occur for reasons like equipment availability, quality control testing, scheduling, cleaning, or transport, and materials must remain under controlled conditions (refrigeration, freezing, controlled room temperature, nitrogen blanketing, light protection) throughout.

Related to this article

Pharma Logistician Using IoT Based On Blockchain | Image Credit: ©leowolfert -stock.adobe.com
Michael Levy, senior vice president, Digital & Innovation, USP, explains the digital supply chain in a preview of his upcoming CPHI Milan panel presentation, The Next Phase of Pharma Supply Chains.
AAPS PharmSci 360: CMC Strategies, Part 3
In a preview of their panel discussion at AAPS PharmSci 360 2026, Alfred Rumondor, PhD, AbbVie, and Swita Singh, PhD, Bristol Myers Squibb, discuss the implementation of risk-based approaches for CMC.